These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 17314684)

  • 1. Sitaxsentan for the prevention of experimental shunt-induced pulmonary hypertension.
    Rondelet B; Kerbaul F; Vivian GF; Hubloue I; Huez S; Fesler P; Remmelink M; Brimiouille S; Salmon I; Naeije R
    Pediatr Res; 2007 Mar; 61(3):284-8. PubMed ID: 17314684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sildenafil added to sitaxsentan in overcirculation-induced pulmonary arterial hypertension.
    Rondelet B; Dewachter L; Kerbaul F; Dewachter C; Hubloue I; Fesler P; Franck S; Remmelink M; Brimioulle S; Naeije R
    Am J Physiol Heart Circ Physiol; 2010 Oct; 299(4):H1118-23. PubMed ID: 20693396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signaling molecules in overcirculation-induced pulmonary hypertension in piglets: effects of sildenafil therapy.
    Rondelet B; Kerbaul F; Van Beneden R; Motte S; Fesler P; Hubloue I; Remmelink M; Brimioulle S; Salmon I; Ketelslegers JM; Naeije R
    Circulation; 2004 Oct; 110(15):2220-5. PubMed ID: 15466636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension.
    Rondelet B; Kerbaul F; Motte S; van Beneden R; Remmelink M; Brimioulle S; McEntee K; Wauthy P; Salmon I; Ketelslegers JM; Naeije R
    Circulation; 2003 Mar; 107(9):1329-35. PubMed ID: 12628956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of pulmonary vascular remodeling and of decreased BMPR-2 expression by losartan therapy in shunt-induced pulmonary hypertension.
    Rondelet B; Kerbaul F; Van Beneden R; Hubloue I; Huez S; Fesler P; Remmelink M; Brimioulle S; Salmon I; Naeije R
    Am J Physiol Heart Circ Physiol; 2005 Dec; 289(6):H2319-24. PubMed ID: 16024566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelin A receptor blockade improves regression of flow-induced pulmonary vasculopathy in piglets.
    Mercier O; Sage E; Izziki M; Humbert M; Dartevelle P; Eddahibi S; Fadel E
    J Thorac Cardiovasc Surg; 2010 Sep; 140(3):677-83. PubMed ID: 20723731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged overcirculation-induced pulmonary arterial hypertension as a cause of right ventricular failure.
    Rondelet B; Dewachter C; Kerbaul F; Kang X; Fesler P; Brimioulle S; Naeije R; Dewachter L
    Eur Heart J; 2012 Apr; 33(8):1017-26. PubMed ID: 21606077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of STRIDE-2 and STRIDE-2X: the case for selective endothelin receptor blockade.
    Langleben D; Cacoub P
    Eur J Clin Invest; 2009 Jun; 39 Suppl 2():27-31. PubMed ID: 19335744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist.
    Tilton RG; Munsch CL; Sherwood SJ; Chen SJ; Chen YF; Wu C; Block N; Dixon RA; Brock TA
    Pulm Pharmacol Ther; 2000; 13(2):87-97. PubMed ID: 10799286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sitaxsentan, a selective endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension.
    Horn EM; Widlitz AC; Barst RJ
    Expert Opin Investig Drugs; 2004 Nov; 13(11):1483-92. PubMed ID: 15500395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease.
    Girgis RE; Frost AE; Hill NS; Horn EM; Langleben D; McLaughlin VV; Oudiz RJ; Robbins IM; Seibold JR; Shapiro S; Tapson VF; Barst RJ
    Ann Rheum Dis; 2007 Nov; 66(11):1467-72. PubMed ID: 17472992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sitaxsentan for treatment of pulmonary hypertension.
    Wittbrodt ET; Abubakar A
    Ann Pharmacother; 2007 Jan; 41(1):100-5. PubMed ID: 17164394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension.
    Barst RJ
    Expert Opin Pharmacother; 2007 Jan; 8(1):95-109. PubMed ID: 17163810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelin receptor antagonists in pulmonary arterial hypertension.
    Dupuis J; Hoeper MM
    Eur Respir J; 2008 Feb; 31(2):407-15. PubMed ID: 18238950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective and mixed endothelin receptor antagonism in cardiovascular disease.
    Dhaun N; Pollock DM; Goddard J; Webb DJ
    Trends Pharmacol Sci; 2007 Nov; 28(11):573-9. PubMed ID: 17950470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Greater functional ETB receptor antagonism with bosentan than sitaxsentan in healthy men.
    MacIntyre IM; Dhaun N; Lilitkarntakul P; Melville V; Goddard J; Webb DJ
    Hypertension; 2010 Jun; 55(6):1406-11. PubMed ID: 20404221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelin receptor antagonism in pulmonary arterial hypertension--a role for selective ET(A) inhibition?
    Jacobs A; Preston IR; Gomberg-Maitland M
    Curr Med Res Opin; 2006 Dec; 22(12):2567-74. PubMed ID: 17166339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up study.
    Langleben D; Hirsch AM; Shalit E; Lesenko L; Barst RJ
    Chest; 2004 Oct; 126(4):1377-81. PubMed ID: 15486408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sitaxsentan in the management of pulmonary arterial hypertension.
    Benedict NJ
    Am J Health Syst Pharm; 2007 Feb; 64(4):363-8. PubMed ID: 17299175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan.
    Benza RL; Mehta S; Keogh A; Lawrence EC; Oudiz RJ; Barst RJ
    J Heart Lung Transplant; 2007 Jan; 26(1):63-9. PubMed ID: 17234519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.